The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

BCL2 Inhibitor Venetoclax for Acute Myeloid Leukemia

Targeted apoptosis induction in elderly and unfit AML patients

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Hematoloji department. Book Appointment →

What is BCL2 Inhibitor Venetoclax for Acute Myeloid Leukemia?

Venetoclax selectively binds and inhibits BCL2 anti-apoptotic protein restoring intrinsic apoptosis pathway in malignant cells.

Combination with hypomethylating agents (azacitidine, decitabine) or low-dose cytarabine produces synergistic anti-leukemic activity.

Mechanism involves displacement of pro-apoptotic BIM from BCL2 sequestration triggering apoptotic cell death.

Approved for newly diagnosed AML in adults 75 years or older or those with comorbidities precluding intensive chemotherapy.

Response rates 60-70% with combination therapy including substantial complete remission rates in this difficult-to-treat population.

Symptoms

AML presentation includes fatigue, infections, bleeding from cytopenias and constitutional symptoms.
Elderly and unfit patients historically had limited treatment options with poor outcomes from supportive care alone.
Pre-treatment evaluation includes performance status, comorbidity assessment and AML genetics for therapy selection.
Tumor lysis syndrome monitoring required during venetoclax dose ramp-up with hyperhydration and rasburicase prophylaxis.
Treatment-related cytopenias require dose modification and supportive care strategies.

Risk Factors

Advanced age, comorbidities and poor performance status historically associated with poor AML outcomes now have effective options.
AML genetics including IDH1/2, FLT3, NPM1 mutations influence treatment response and may guide combination selection.
TP53 mutations confer resistance to venetoclax-based therapy though some response observed.
Tumor lysis syndrome risk highest with high tumor burden requiring careful ramp-up dosing.
Drug-drug interactions with CYP3A4 inhibitors require dose adjustments to prevent toxicity.

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Newly diagnosed AML in elderly or unfit patients warrants venetoclax combination consideration.
  • Treatment-related cytopenias including febrile neutropenia require prompt evaluation and supportive care.
  • Tumor lysis syndrome signs including hyperkalemia, hyperuricemia, renal dysfunction require urgent management.
  • Drug interactions particularly with antifungal agents (voriconazole, posaconazole) require dose adjustments.
  • Disease progression on venetoclax-based therapy warrants reassessment and alternative therapy consideration.

Treatment Methods

01
Venetoclax ramp-up from 100 mg day 1, 200 mg day 2, 400 mg daily from day 3 with comprehensive tumor lysis monitoring.
02
Combination with azacitidine 75 mg/m2 daily for 7 days every 28 days as standard regimen for elderly AML.
03
Combination with decitabine 20 mg/m2 daily for 5 days every 28 days as alternative regimen.
04
Combination with low-dose cytarabine 20 mg/m2 daily for 10 days every 28 days for selected patients.
05
Comprehensive supportive care including transfusion support for cytopenias, infection prophylaxis with antifungal and antibacterial agents, treatment of febrile neutropenia, dose modifications for cytopenias and toxicities, monitoring for disease response with bone marrow assessment and management of long-term toxicities optimizes outcomes in this previously poor-prognosis population.

Which Department to Visit?

You can visit our Hematoloji department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Hematoloji Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.